Results 251 to 260 of about 13,263,091 (289)
Some of the next articles are maybe not open access.
Cyclophosphamide and Etoposide for Non-Small Cell and Small Cell Lung Cancer
Drugs, 1999Oral chemotherapeutic regimens with limited toxicity are desirable in that quality of life can be maintained and clinic/hospital visits minimised during therapy. We have investigated the use of extended courses of oral cyclophosphamide and oral etoposide for the treatment of non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). A 14-day
openaire +2 more sources
Small cell carcinoma of the larynx
American Journal of Otolaryngology, 1994(Editorial Comment: These authors report a good response in patients treated for small cell carcinoma of the larynx with combination chemotherapy, including cisplatin and etoposide. Further observation will need to be made to corroborate these findings.) Primary small cell carcinoma (SCC) of the larynx is a rare malignancy associated with frequent ...
L, Soylu +9 more
openaire +3 more sources
Small cell carcinoma of the gallbladder
Journal of Surgical Oncology, 1999Small cell carcinoma of the gallbladder is rare with only 36 cases reported in the literature. Early reports demonstrated an extremely poor prognosis for this histologic type. Five new cases are reported and the previous experience in the literature is reviewed to further clarify the clinical behavior of this malignancy.A retrospective analysis is ...
T L, Moskal, P J, Zhang, H R, Nava
openaire +2 more sources
Small molecules for stem cells
Expert Opinion on Therapeutic Patents, 2009Embryonic stem cells are pluripotent cells that can differentiate to any cell type. Stem-cell research promises great progress in regenerative medicine to replace damaged tissues and organs.There are two key scientific questions: i) what causes stem cells to maintain an undifferentiated state; and ii) what signals affect/initiate differentiation ...
openaire +2 more sources
Small cell bronchogenic carcinoma
Current Problems in Cancer, 1986We have attempted to highlight the most important aspects of SCBC in this review. The significant strides made in a variety of areas have been associated with increased response rates and survival as well as with a prolonged disease-free interval in a fraction of patients.
M, Perloff, J Y, Killen, R E, Wittes
openaire +2 more sources
Therapy for small cell and non-small cell lung cancer
Current Opinion in Oncology, 1990C P, Belani, J, Aisner
openaire +2 more sources
Critical Care Management of Chimeric Antigen Receptor T-Cell Therapy Recipients
Ca-A Cancer Journal for Clinicians, 2022Sandrine Valadè +2 more
exaly